The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers

Inclusion Criteria: 1. Male or female 18 to 65 years of age 2. Body mass index (BMI) 18.0 to 30.0 kg/m2. 3. Never-smoker Exclusion Criteria: 1. Body weight \<50 kg 2. Donation of blood (450 mL) or blood loss within 3 months prior to study 3. Contraindication, allergy, or hypersensitivity to hydroxychloroquine or chloroquine or other 4 aminoquinolines 4. Use of any prescription or OTC medications or herbal supplements within 2 weeks (or 5half-lives if longer) prior to study 5. Use of any investigational product/medical device within 30 days or 5 half-lives prior to study, or participation in ≥4 investigational drug studies within 1 year prior to study 6. History or presence of any of the following conditions: * Autoimmune or rheumatoid inflammatory disease * Cardiac disorders * Lung disease, prior intubation, or requiring use of an inhaler * Liver cirrhosis or Child-Pugh class C * Retinopathy or maculopathy * Neuromuscular diseases * Glucose-6 phosphate dehydrogenase deficiency * Hematologic malignancy * Chronic kidney disease or renal failure * Psoriasis or porphyria * Diabetes mellitus * Severe allergic or anaphylactic reactions * Any other significant condition that would preclude participation 7. History of substance abuse or dependency in the last 12 months, or a history of recreational intravenous drug use over the last 5 years 8. Fever or symptomatic viral or bacterial infection within 2 weeks prior to study 9. Any clinically significant laboratory abnormality